Table 1.
Odds Ratios for the Development of Bronchiolitis Obliterans Syndrome by 30 Months Post Lung Transplantation as Predicted by Immune Mediators Measured in Bronchoalveolar Fluid at 6 to 12 Months after Lung Transplantation
| Protein | Concentration, per mg protein | |
|---|---|---|
| Odds ratio | 95% CI | |
| C5a | 1.26 | 0.31–5.10 |
| IL-1β | 0.94 | 0.66–1.35 |
| IL-1RA | 1.48 | 0.88–2.48 |
| IL-2 | 1.05 | 0.66–1.67 |
| IL-4 | 0.80 | 0.39–1.63 |
| IL-5 | 0.84 | 0.34–2.08 |
| IL-6 | 1.12 | 0.64–1.96 |
| IL-7 | 1.06 | 0.68–1.64 |
| IL-8 | 1.04 | 0.67–1.60 |
| IL-9 | 1.38 | 0.83–2.28 |
| IL-10 | 0.75 | 0.49–1.15 |
| IL-12 | 0.86 | 0.51–1.45 |
| IL-13 | 1.20 | 0.80–1.80 |
| IL-15 | 1.57 | 1.01–2.44 |
| IL-17 | 1.50 | 1.00–2.24 |
| Eotaxin | 1.06 | 0.82–1.36 |
| bFGF | 1.41 | 1.02–1.93 |
| G-CSF | 0.93 | 0.58–1.49 |
| GM-CSF | 1.26 | 0.71–2.22 |
| IFN-γ | 0.85 | 0.64–1.13 |
| IP-10 | 1.28 | 0.72–2.27 |
| MCP-1 | 1.17 | 0.68–2.01 |
| MIP-1α | 1.31 | 0.73–2.36 |
| MIP-1β | 1.64 | 0.85–3.19 |
| PDGF | 1.17 | 0.82–1.67 |
| RANTES | 0.89 | 0.67–1.19 |
| TGF-β | 0.71 | 0.24–2.08 |
| TNF-α | 2.03 | 1.27–3.23 |
| VEGF | 1.09 | 0.71–1.68 |
| MPO | 3.22 | 1.22–8.50 |
| A1AT | 0.24 | 0.08–0.78 |
| NE | 1.07 | 0.87–1.30 |
| A1AT/NE | 0.87 | 0.55–1.38 |
| Pepsin | 1.08 | 0.75–1.55 |
A1AT, α1-antitrypsin; bFGF, basic fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP-10, interferon-γ–induced protein 10; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory factor; MPO, myeloperoxidase; NE, neutrophil elastase; PDGF, platelet-derived growth factor; RANTES, regulated upon activation, normal T-cell expressed and secreted; TGF, transforming growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.